NKGen Biotech (NKGN) Insider Trading & Ownership $0.13 +0.01 (+8.41%) As of 04/15/2025 03:54 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NKGen Biotech (NYSE:NKGN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.36%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$1,261.12Number OfInsiders Selling(Last 3 Years)0 Get NKGN Insider Trade Alerts Want to know when executives and insiders are buying or selling NKGen Biotech stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NKGN Insider Buying and Selling by Quarter Remove Ads NKGen Biotech Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/6/2023Paul Y SongCEOBuy75$3.32$249.00 11/27/2023Paul Y SongCEOBuy244$2.88$702.72 11/21/2023Paul Y SongCEOBuy100$2.80$280.00 11/20/2023James A GrafCFOBuy10$2.94$29.40 (Data available from 1/1/2013 forward) NKGN Insider Trading Activity - Frequently Asked Questions Who is on NKGen Biotech's Insider Roster? The list of insiders at NKGen Biotech includes James A Graf, and Paul Y Song. Learn more on insiders at NKGN. What percentage of NKGen Biotech stock is owned by insiders? 10.36% of NKGen Biotech stock is owned by insiders. Learn more on NKGN's insider holdings. Which NKGen Biotech insiders have been buying company stock? The following insiders have purchased NKGN shares in the last 24 months: James A Graf ($29.40), and Paul Y Song ($1,231.72). How much insider buying is happening at NKGen Biotech? Insiders have purchased a total of 429 NKGN shares in the last 24 months for a total of $1,261.12 bought. NKGen Biotech Key ExecutivesDr. Paul Y. Song M.D. (Age 58)CEO & Chairman Compensation: $36.58MMr. Sangwoo Park (Age 54)Executive Director Compensation: $576kMr. James A. Graf (Age 59)Interim CFO Mr. Pierre Gagnon (Age 52)Chief Operating Officer Ms. Yoonmi KangVice President of Technical OperationsDr. Yong Man Kim Ph.D. (Age 59)Chief Scientific Officer Ms. Denise A. Chua CLSMBA, MT (ASCP), Vice President of Investor Relations & Corporate CommunicationsMs. Irene ChangVice President of Human ResourcesMr. Ryan Park C.F.A.SVP of Financial Planning & Analysis and Corporate Strategy More Insider Trading Tools from MarketBeat Related Companies Surrozen Insider Selling Kezar Life Sciences Insider Selling SCYNEXIS Insider Selling Coeptis Therapeutics Insider Selling OS Therapies Insider Selling Aligos Therapeutics Insider Selling NRx Pharmaceuticals Insider Selling Marinus Pharmaceuticals Insider Selling Lantern Pharma Insider Selling ALX Oncology Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Beware of BigBear.ai: Insiders Are Selling—Should You?Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market SentimentMicroStrategy Sees Insider Buy-Sell Action in Q1Casey’s General Stores Insider Buys Shares of This Must-Own Stock This page (NYSE:NKGN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.